Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Bridget L. Morse"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 2, Pp 173-184 (2022)
Abstract Tadalafil, a phosphodiesterase 5 inhibitor, is being investigated as a treatment for pulmonary arterial hypertension (PAH) in children aged 6 months to less than 18 years. Tadalafil pharmacokinetic (PK) data in children less than 2 years old
Externí odkaz:
https://doaj.org/article/7128df2f20344123b96b10b8721c5078
Autor:
Bridget L. Morse, Jeffrey J. Alberts, Maria M. Posada, Jessica Rehmel, Anil Kolur, Lai San Tham, Corina Loghin, Kathleen M. Hillgren, Stephen D. Hall, Gemma L. Dickinson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 664-675 (2019)
The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs). Drugs that affect gastric emptying, including dulaglutide, also affect atorv
Externí odkaz:
https://doaj.org/article/2a273e5063874e24aca5d62fecd6337f
Autor:
Bridget L. Morse, Lisa Hong Chen, John T. Catlow, John K. Fallon, Philip C. Smith, Kathleen M. Hillgren
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
The role of organic cation transporter 1 (OCT1) in humans is gaining attention as data emerges regarding its role in physiology, drug exposure, and drug response. OCT1 variants with decreased in vitro function correlate well with altered exposure of
Externí odkaz:
https://doaj.org/article/0052c40fa9564f39aeb93353b20d9483
Autor:
P. Kellie Turner, Gemma L. Dickinson, Stephen D. Hall, Palaniappan Kulanthaivel, Bridget L. Morse, Maria M. Posada
Publikováno v:
Journal of Clinical Pharmacology
Abemaciclib, a selective inhibitor of cyclin‐dependent kinases 4 and 6, is metabolized mainly by cytochrome P450 (CYP)3A4. Clinical studies were performed to assess the impact of strong inhibitor (clarithromycin) and inducer (rifampin) on the expos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45018a1d0ee7bc2064b8d005c468badd
https://doi.org/10.1002/jcph.1584
https://doi.org/10.1002/jcph.1584
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 2, Pp 173-184 (2022)
Tadalafil, a phosphodiesterase 5 inhibitor, is being investigated as a treatment for pulmonary arterial hypertension (PAH) in children aged 6 months to less than 18 years. Tadalafil pharmacokinetic (PK) data in children less than 2 years old are unav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5d8ec7b3862f7282e30f9d7e2092c9
https://pubmed.ncbi.nlm.nih.gov/34800000
https://pubmed.ncbi.nlm.nih.gov/34800000
Autor:
Kathleen M. Hillgren, Bridget L. Morse, Lai San Tham, Maria M. Posada, Gemma L. Dickinson, Stephen D. Hall, Corina Loghin, Jessica Rehmel, Anil Kolur, Jeffrey J. Alberts
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 664-675 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs). Drugs that affect gastric emptying, including dulaglutide, also affect atorv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2440c74a085f6fbbce159b840e0088
https://doi.org/10.1002/psp4.12447
https://doi.org/10.1002/psp4.12447
Autor:
John K. Fallon, Philip C. Smith, Kathleen M. Hillgren, Anil Kolur, Bridget L. Morse, Andrew T Hogan
Publikováno v:
The AAPS Journal. 23
Hepatic clearance may be uptake rate limited by organic anion transporting polypeptides (OATPs) and organic cation transporter 1 (OCT1). While comparison of OATP activity has been investigated across species, little has been reported for OCT1. Additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c536eb63ed200a9c2ba6a1b6ffbc8d2a
https://doi.org/10.1208/s12248-021-00583-z
https://doi.org/10.1208/s12248-021-00583-z
Autor:
Lisa Hong Chen, John K. Fallon, Philip C. Smith, John T. Catlow, Kathleen M. Hillgren, Bridget L. Morse
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
The role of organic cation transporter 1 (OCT1) in humans is gaining attention as data emerges regarding its role in physiology, drug exposure, and drug response. OCT1 variants with decreased in vitro function correlate well with altered exposure of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8123d96d54da82b841f22dd096703043
http://europepmc.org/articles/PMC7917185
http://europepmc.org/articles/PMC7917185
Publikováno v:
AAPS J
Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid present endogenously in the brain and used therapeutically for the treatment of narcolepsy, as sodium oxybate, and for alcohol abuse/withdrawal. GHB is better known however as a drug of abuse an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223972f84f4c6b7cc43c90393b5ddf0e
https://doi.org/10.1208/s12248-020-00543-z
https://doi.org/10.1208/s12248-020-00543-z
Autor:
Wendy A. Teft, Bridget L. Morse, Robert A. Hegele, Richard B. Kim, Steven E. Gryn, Cheynne McLean
Publikováno v:
Clinical Pharmacology & Therapeutics. 104:525-533
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter-mediated accumulation in the liver enhances its efficacy. Current guidelines indicate no preference for fed or fasted rosuvastatin administration. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f56c31768bcad817e3943caadcb0b6e
https://doi.org/10.1002/cpt.973
https://doi.org/10.1002/cpt.973